MX2022013884A - Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia. - Google Patents

Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia.

Info

Publication number
MX2022013884A
MX2022013884A MX2022013884A MX2022013884A MX2022013884A MX 2022013884 A MX2022013884 A MX 2022013884A MX 2022013884 A MX2022013884 A MX 2022013884A MX 2022013884 A MX2022013884 A MX 2022013884A MX 2022013884 A MX2022013884 A MX 2022013884A
Authority
MX
Mexico
Prior art keywords
methylthioninium
hypoxemia
compounds
treatment
alleviating
Prior art date
Application number
MX2022013884A
Other languages
English (en)
Inventor
Michael Philip Mazanetz
Claude Michel Wischik
Mohammad Arastoo
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006659.3A external-priority patent/GB202006659D0/en
Priority claimed from GBGB2016957.9A external-priority patent/GB202016957D0/en
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MX2022013884A publication Critical patent/MX2022013884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para aliviar hipoxemia en un sujeto a través de administración oral de un compuesto de metiltioninio.
MX2022013884A 2020-05-05 2021-04-30 Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia. MX2022013884A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006659.3A GB202006659D0 (en) 2020-05-05 2020-05-05 Therapeutic treatments
GBGB2016957.9A GB202016957D0 (en) 2020-10-26 2020-10-26 Beneficial treatment
PCT/EP2021/061485 WO2021224146A1 (en) 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of hypoxemia

Publications (1)

Publication Number Publication Date
MX2022013884A true MX2022013884A (es) 2022-11-30

Family

ID=75887990

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013884A MX2022013884A (es) 2020-05-05 2021-04-30 Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia.

Country Status (12)

Country Link
US (1) US20230158040A1 (es)
EP (1) EP4146225B1 (es)
JP (1) JP2023524146A (es)
KR (1) KR20230012515A (es)
CN (1) CN115916211A (es)
AU (1) AU2021268465A1 (es)
CA (1) CA3181388A1 (es)
ES (1) ES2992641T3 (es)
MX (1) MX2022013884A (es)
PL (1) PL4146225T3 (es)
TW (1) TWI907424B (es)
WO (1) WO2021224146A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
US20060264423A1 (en) 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) * 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
EP3982974A4 (en) * 2019-06-12 2023-06-21 Achal Narendrakumar Agrawal NOVEL IMPROVED PROCESS FOR THE SYNTHESIS OF DIAMINOPHENOTHIAZINE COMPOUNDS

Also Published As

Publication number Publication date
EP4146225B1 (en) 2024-10-09
TW202200149A (zh) 2022-01-01
BR112022022322A2 (pt) 2022-12-13
ES2992641T3 (en) 2024-12-16
TWI907424B (zh) 2025-12-11
CN115916211A (zh) 2023-04-04
JP2023524146A (ja) 2023-06-08
WO2021224146A1 (en) 2021-11-11
US20230158040A1 (en) 2023-05-25
PL4146225T3 (pl) 2025-03-10
AU2021268465A1 (en) 2022-12-08
EP4146225C0 (en) 2024-10-09
EP4146225A1 (en) 2023-03-15
KR20230012515A (ko) 2023-01-26
CA3181388A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
JOP20220142A1 (ar) مثبطات kras g12c
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
NZ744567A (en) Treatment of cancers using pi3 kinase isoform modulators
TN2019000210A1 (en) Antitumoral compounds
EA202193015A1 (ru) Ингибиторы cdk
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
MX2013012588A (es) Inhibidores de cinasa.
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
MY190408A (en) Compositions and methods for treating cns disorders
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
PH12016502355B1 (en) Pharmaceutical composition
MX346186B (es) Inhibidores de proteina cinasas.
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
PH12014502547A1 (en) Dosage regimen for a pi-3 kinase inhibitor
ZA202000028B (en) Use of vibegron to treat overactive bladder
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2022013884A (es) Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia.
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
MX2023008083A (es) Tratamiento conjunto.
PH12019500960A1 (en) 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
MX2013012486A (es) Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).
MX2020005168A (es) Formas de dosificacion que contienen un inhibidor calicreina de plasma.
MX2022013883A (es) Compuestos de metiltioninio para uso en el tratamiento de covid-19.
PH12021550248A1 (en) Borate of azetidine derivative